UGT and FMO Ontogeny in Pediatric PBPK

Why UGT and FMO Ontogeny Requires Pathway-Specific Treatment

A pediatric PBPK model can predict clearance poorly even when its body size, liver size, and blood flow are represented appropriately. One reason is that metabolic capacity is not a single age-varying quantity: a drug may undergo glucuronidation through one or more UDP-glucuronosyltransferase (UGT) pathways and oxidation through a flavin-containing monooxygenase (FMO) pathway, with each pathway having its own developmental profile. Immature activity in one route does not establish that all UGTs or all FMOs are equally immature.

The practical task is therefore to connect evidence for a particular enzyme pathway and substrate to that pathway’s contribution to intrinsic clearance. The result is a pathway-specific age adjustment, not a blanket “pediatric enzyme factor.” The introductory material on age-dependent hepatic enzyme abundance and capacity provides the general capacity framework; here the focus is how to apply it carefully to UGT and FMO routes.

For UGTs, evidence must be relevant to the enzyme(s) that glucuronidate the drug, rather than merely to “UGT activity” in general. For FMOs, the relevant evidence likewise depends on the FMO isoform and the oxidative reaction being modeled. In either case, a measured developmental change in abundance may not equal the same change in catalytic activity for every substrate. A useful evidence record therefore identifies the enzyme or pathway, tissue, age definition, assay substrate and conditions, and the normalization used to report activity.

From Pathway Evidence to Clearance

If several metabolic routes contribute to the same drug’s elimination, their intrinsic clearance contributions add under the usual parallel-pathway representation. This assumes that the pathway-specific intrinsic clearances have been defined on compatible bases and that the relevant kinetics are adequately linear over the concentration range of interest.

The sum can include separate UGT and FMO routes, as well as other metabolic pathways when they are in scope. Do not apply one maturation multiplier to the summed adult clearance unless there is evidence that the routes mature proportionally. Doing so silently imposes the same age profile on pathways that may have different evidence.

For a well-stirred liver model, hepatic clearance is related to total hepatic intrinsic clearance by hepatic blood flow and the unbound fraction in blood. In the following equation \(Q_h\) is hepatic blood flow and \(f_{u,b}\) is the unbound fraction in blood. The model assumes a well-mixed liver, linear intrinsic clearance, and that these parameters represent the modeled age and conditions.

This relation matters because a proportional decrease in intrinsic clearance does not always produce the same proportional decrease in hepatic clearance. When \(f_{u,b}CL_{\mathrm{int}}\) is small relative to \(Q_h\), hepatic clearance is approximately \(f_{u,b}CL_{\mathrm{int}}\), so a change in intrinsic clearance is transmitted strongly. When intrinsic clearance is large relative to flow, hepatic clearance approaches \(Q_h\), and further increases in enzyme capacity have less effect on clearance.

Combining UGT and FMO Contributions

The sum of parallel pathways is the key step when glucuronidation and oxidation both contribute. A low maturation multiplier for one route does not automatically mean low total metabolism: another route may contribute substantially or may have a different developmental profile. Conversely, assuming an alternative route compensates for immature conjugation without evidence can overpredict clearance.

Derivation: Why Pathway Contributions Add Before the Liver Model

The pathway sum follows from parallel metabolic removal in the linear regime. At a given unbound drug concentration in the liver, let route \(j\) remove drug at rate \(v_j=CL_{\mathrm{int},j}C_u\), where \(C_u\) is the relevant unbound concentration. The total metabolic removal rate is the sum of the route-specific rates:

By the definition of intrinsic clearance, the factor multiplying \(C_u\) is total intrinsic clearance. If each route changes with age through its own multiplier, substitution gives \(CL_{\mathrm{int}}(a)=\sum_j M_j(a)CL_{\mathrm{int},j,\mathrm{adult}}\). This derivation depends on the linear-rate representation; saturable kinetics, substrate competition, or a mismatch in the underlying assay basis can make a simple sum inadequate. It also shows why one must scale each route before summing rather than multiply the sum by an unsupported common factor.

Evidence Checks, Failure Modes, and Alternatives

Before using an ontogeny multiplier, check whether the evidence supports the intended inference. An expression measurement, a protein abundance measurement, and a substrate-specific activity assay are not interchangeable without a justified link. The assay should reflect the relevant reaction and should be interpreted with its cofactors, incubation conditions, and normalization in view. Sparse ages or inconsistent assays may support a broad uncertainty range rather than a precise age curve.

• Do not treat all UGTs as one enzyme. A drug’s relevant glucuronidation route may not follow the profile of a different UGT or a pooled assay.
• Do not treat all FMOs as one pathway. The relevant isoform and reaction should match the drug’s oxidative metabolism.
• Do not multiply twice. If an age-specific activity estimate already represents the scaled pathway clearance, do not apply the same maturation multiplier again.
• Check the reference. A multiplier is meaningful only when its denominator is clear—for example, adult activity in a specified assay. An unusual value may reflect the chosen reference, assay variability, or true age-specific activity.
• Check the linearity assumption. If substrate concentrations approach saturation or pathways interact, simple additive intrinsic clearances may not capture the kinetics.

A pathway-specific multiplier is generally more defensible than a single global enzyme factor when evidence differs by route. Where data are too sparse to distinguish pathways, a conservative model may use explicit alternative parameterizations and examine the resulting clearance predictions rather than imply certainty. A direct age-specific intrinsic-clearance estimate can also be used if it is supported by suitable evidence; it should not be combined with an additional ontogeny adjustment that would count the same developmental effect twice. These are alternatives in parameterization, not substitutes for documenting the biochemical basis of the estimate.

A common mistake is to reason, “UGT activity is low early in life, so total hepatic clearance must be low by the same percentage.” This is incorrect because the drug may have multiple pathways, each with distinct maturation, and hepatic clearance also depends on blood flow and unbound fraction. The correction is to scale each supported pathway separately, add the age-specific intrinsic-clearance contributions, and then use the appropriate hepatic model and age-specific physiological inputs.